PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.
The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.
PolyPid (Nasdaq: PYPD), una società biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato la sua partecipazione al prossimo Lytham Partners Spring 2025 Investor Conference. L'evento virtuale si terrà il 29 maggio 2025.
La società terrà una presentazione in webcast alle 10:15 a.m. ET e svolgerà incontri individuali con gli investitori durante tutta la durata dell'evento. La presentazione sarà accessibile tramite il sito web della conferenza e sarà disponibile per la visione in differita dopo l'evento.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada enfocada en mejorar los resultados quirúrgicos, ha anunciado su participación en la próxima Lytham Partners Spring 2025 Investor Conference. El evento virtual se llevará a cabo el 29 de mayo de 2025.
La compañía realizará una presentación por webcast a las 10:15 a.m. ET y llevará a cabo reuniones individuales con inversores durante todo el evento. La presentación estará accesible a través del sitio web de la conferencia y estará disponible para reproducción después del evento.
PolyPid (나스닥: PYPD)은 수술 결과 개선에 중점을 둔 후기 단계 바이오제약 회사로, 다가오는 Lytham Partners Spring 2025 Investor Conference에 참여한다고 발표했습니다. 이 가상 행사는 2025년 5월 29일에 열립니다.
회사는 동부 표준시 오전 10시 15분에 웹캐스트 발표를 진행하며, 행사 기간 동안 투자자들과 일대일 미팅을 가질 예정입니다. 발표는 컨퍼런스 웹사이트를 통해 접속할 수 있으며, 행사 후 다시보기로도 제공됩니다.
PolyPid (Nasdaq : PYPD), une société biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la prochaine Lytham Partners Spring 2025 Investor Conference. L'événement virtuel aura lieu le 29 mai 2025.
L'entreprise présentera un webcast à 10h15 ET et tiendra des réunions individuelles avec les investisseurs tout au long de l'événement. La présentation sera accessible via le site web de la conférence et disponible en replay après l'événement.
PolyPid (Nasdaq: PYPD), ein Biopharmaunternehmen in der Endphase, das sich auf die Verbesserung chirurgischer Ergebnisse spezialisiert hat, hat seine Teilnahme an der bevorstehenden Lytham Partners Spring 2025 Investor Conference angekündigt. Die virtuelle Veranstaltung findet am 29. Mai 2025 statt.
Das Unternehmen wird um 10:15 Uhr ET eine Webcast-Präsentation halten und während der Veranstaltung Einzelgespräche mit Investoren führen. Die Präsentation ist über die Konferenzwebsite zugänglich und wird nach der Veranstaltung als Wiedergabe verfügbar sein.
- None.
- None.
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
Company Webcast
The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/QyL1ZkGZK8z. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2025invreg/.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid (PYPD) presenting at the Lytham Partners Spring 2025 Conference?
How can investors access PolyPid's (PYPD) presentation at the Lytham Partners Conference?
How can investors arrange one-on-one meetings with PolyPid (PYPD) management?
What is PolyPid's (PYPD) main business focus?
